Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy.
Adolescent
Agammaglobulinemia
/ chemically induced
B-Lymphocyte Subsets
Female
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Immunoglobulin Class Switching
Immunoglobulin G
Lymphoproliferative Disorders
/ drug therapy
Postoperative Complications
/ drug therapy
Rituximab
/ adverse effects
Transplantation, Homologous
Allogeneic hematopoietic stem cell transplantation
Hypogammaglobulinemia
Monoclonal protein
Post-transplant lymphoproliferative disorder
Rituximab
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
25
11
2019
accepted:
15
04
2020
revised:
06
04
2020
pubmed:
29
4
2020
medline:
11
11
2020
entrez:
29
4
2020
Statut:
ppublish
Résumé
Post-transplant lymphoproliferative disorder (PTLD) is one of the most serious complications of allogeneic hematopoietic stem cell transplantation (HSCT). Rituximab is effective for PTLD; however, rituximab can produce adverse effects, including hypogammaglobulinemia. Here, we present the case of an 18-year-old female with refractory cytopenia of childhood who developed persistent selective hypogammaglobulinemia with low immunoglobulin G (IgG) 2 and IgG4 levels and monoclonal protein after rituximab therapy against probable PTLD. Despite B-cell recovery, the serum IgG levels gradually declined, reaching < 300 mg/dL at 33 months after rituximab treatment. In addition, class-switched memory (CD27
Identifiants
pubmed: 32342335
doi: 10.1007/s12185-020-02886-x
pii: 10.1007/s12185-020-02886-x
doi:
Substances chimiques
Immunoglobulin G
0
Rituximab
4F4X42SYQ6
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM